Thrilled to announce we are leading the $6.5M seed round for Dash Bio - a new robotics startup helping to get miracle drugs to market cheaper and faster! 🧪💊https://t.co/2qLODJf74O
Moderna Alums Launch Biotech-Services Startup Dash Bio #DisruptiveTech https://t.co/EgGwvnns4M
Some of Dash Bio's seed investors incl Swift Ventures/@bjwilson34, @freestylevc/@mariabrw & LifeX Ventures. Their robotics & clinical bioanalysis lab is in Newton, MA. They are also able to work w/CROs 1/n https://t.co/1imHeWj893
Three startups have recently announced successful funding rounds. Augmental Technologies, after nearly five years of development, secured a $4 million seed round led by SCI Ventures, with participation from Murata, Revere Partners, LivEdge Capital, Fen Ventures, CaraoVC, and Tesserakt Ventures. Move AI raised $1.4 million in a pre-seed round led by E14 Fund, with support from Pioneer Fund, Taro Fund, and ten angel investors, including Y Combinator founders. Dash Bio, co-founded by Moderna's former Chief Data & AI Officer Dave Johnson and Ander Tallett, raised $6.5 million in a seed round led by Swift Ventures and Freestyle VC. Dash Bio specializes in bioanalysis from in vivo through clinical studies and is based in Newton, MA.